Filing Flows

Filing Flows › Companies › Century Therapeutics › Cash flow

Century Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$20.5M in Q2 2026 · −$88.1M over twelve months

Operating cash flow−$19.8M
Capital spending−$694K
Free cash flow−$20.5M

Analysis

In Q2 2026, Century Therapeutics generated −$19.8M of operating cash flow and spent $694K on capital projects, leaving free cash flow of −$20.5M. That is $7.4M more than in Q2 2025 (−$27.9M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$86.8M; the largest uses were operating cash flow ($86.8M), other investing ($46.5M), capital spending ($1.3M); besides operations, cash came from other financing ($126M), shares issued ($602K); the cash balance fell by $7.6M.

Operating cash flow was −$19.8M against net income of −$34.5M. The largest differences: stock-based pay +$1.9M, payables +$1.7M, accrued liabilities +$1.2M.

Free cash flow

Century Therapeutics: free cash flow by quarterCentury Therapeutics: free cash flow by quarter−$28.3MQ3 2024−$24.2MQ4 2024−$35.1MQ1 2025−$27.9MQ2 2025−$25.8MQ3 2025−$15.9MQ4 2025−$25.8MQ1 2026−$20.5MQ2 2026
Operating cash flow less capital spending.
Century Therapeutics: operating cash flow against capital spendingCentury Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$28.3M$0Q3 2024−$24.2M$0Q4 2024−$34.6M$475KQ1 2025−$27.6M$317KQ2 2025−$25.6M$195KQ3 2025−$16.1M−$139KQ4 2025−$25.3M$584KQ1 2026−$19.8M$694KQ2 2026
Latest (Q2 2026): Operating cash flow −$19.8M, Capital spending $694K.

Capital allocation, year by year

Century Therapeutics: where the cash came from (up) and went (down), by fiscal yearCentury Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$89.0MFY2021: Shares issued $2.5MFY2021: Capital spending −$45.0M$2.5MFY2021FY2022: Operating cash flow $14.1MFY2022: Shares issued $345KFY2022: Capital spending −$30.6M$14.4MFY2022FY2023: Operating cash flow −$88.3MFY2023: Net borrowing −$10.2MFY2023: Shares issued $516KFY2023: Capital spending −$13.7M$516KFY2023FY2024: Operating cash flow −$110MFY2024: Shares issued $141KFY2024: Capital spending −$154K$141KFY2024FY2025: Operating cash flow −$104MFY2025: Shares issued $173KFY2025: Capital spending −$848K$173KFY2025
Over these 5 years operating cash flow totalled −$377M; the largest uses were operating cash flow ($391M) and capital spending ($90.3M). Cash-flow statements as filed.

Where the cash came from and went

Century Therapeutics: sources (+) and uses (−) of cash, Q2 2026Century Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$19.8MOther investing$18.5MCash drawn (+) / kept (−)$1.8MCapital spending−$694KShares issued$347KOther financing−$36K
Century Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Century Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$126MOperating cash flow−$86.8MOther investing−$46.5MCash drawn (+) / kept (−)$7.6MCapital spending−$1.3MShares issued$602K

From profit to cash

Century Therapeutics: net income to operating cash flow, Q2 2026Century Therapeutics: net income to operating cash flow, Q2 2026Net income−$34.5MDepreciation & amortization$26KStock-based pay$1.9MPayables$1.7MAccrued liabilities$1.2MPrepaid and other assets−$1.2MOperating cash flow−$19.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$19.8M−$694K$347K$1.8M−$20.5M
Q1 2026−$25.3M−$584K$202K$11.3M−$25.8M
Q4 2025−$16.1M$139K$53K−$6.3M−$15.9M
Q3 2025−$25.6M−$195K—$913K−$25.8M
Q2 2025−$27.6M−$317K—−$4.9M−$27.9M
Q1 2025−$34.6M−$475K$120K$6.6M−$35.1M
Q4 2024−$24.2M—−$602K−$5.8M−$24.2M
Q3 2024−$28.3M—$273K−$11.1M−$28.3M

Century Therapeutics: income statement and cash flow

Century Therapeutics, Q1 2025: revenue $109M (128× year over year), operating margin 67.9%. The chart follows the revenue to costs, profit and cash.

Century Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.